This logic has manifested in the newly released guidance to companies interested in pursuing a broad listing for cancer immunotherapies. An expectation of no net cost. Patients, you waited nine years for this, and it was granted on the basis that your treatment cost the government nothing. That is what your life is worth.
Watching this system has become like cheering for an elephant on a unicycle
June 24, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
UQ drug QED-203 moves toward first in human trials with Ellison Medical Institute backing
June 24, 2026 - - Australian Biotech -
Watching this system has become like cheering for an elephant on a unicycle
June 24, 2026 - - Latest News -
Tax deal delays NDIS overhaul and reopens scrutiny with inquiry extension
June 24, 2026 - - Latest News -
Access delays in cancer medicines are costing Australia productivity, livelihoods, and lives
June 23, 2026 - - Latest News -
US launches investigation into pharmaceutical pricing with potential broad implications
June 23, 2026 - - Latest News -
If we're incapable of delivering meaningful change, we should hope the US intervenes
June 23, 2026 - - Latest News -
'AUScelerate' emerges as new name for MTPConnect ahead of BIO 2026
June 22, 2026 - - Australian Biotech


